Daiwa Securities Group Inc. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 196 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$3
+50.0%
1670.0%0.00%
Q2 2023$20.0%1670.0%0.00%
Q1 2023$20.0%1670.0%0.00%
Q4 2022$2
-99.8%
167
+169.4%
0.00%
Q3 2022$1,0000.0%620.0%0.00%
Q2 2022$1,0000.0%620.0%0.00%
Q1 2022$1,0000.0%620.0%0.00%
Q4 2021$1,0000.0%620.0%0.00%
Q3 2021$1,0000.0%620.0%0.00%
Q2 2021$1,0000.0%620.0%0.00%
Q1 2021$1,000
-50.0%
620.0%0.00%
Q4 2020$2,000
-75.0%
62
-66.5%
0.00%
Q3 2020$8,000
-33.3%
1850.0%0.00%
Q2 2020$12,0000.0%1850.0%0.00%
Q1 2020$12,000
-47.8%
1850.0%0.00%
Q4 2019$23,000
+64.3%
185
-9.8%
0.00%
Q3 2019$14,000
-12.5%
2050.0%0.00%
Q2 2019$16,000
-23.8%
205
+8.5%
0.00%
Q1 2019$21,0000.0%189
-9.6%
0.00%
Q4 2018$21,000
+16.7%
209
+50.4%
0.00%
Q3 2018$18,000
+50.0%
1390.0%0.00%
Q2 2018$12,000
+33.3%
1390.0%0.00%
Q1 2018$9,0001390.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2020
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders